PRPH (ProPhase Labs) Probability of Financial Distress (%): 54.87% (As of Jun. 25, 2026)


What is ProPhase Labs Probability of Financial Distress (%)?

ProPhase Labs PRPH -4.61% Probability of Financial Distress (%) is 54.87% as of Jun. 25, 2026. The stock has 4 warning signs investors should review.

Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, ProPhase Labs's Probability of Financial Distress (%) is 54.87%.

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.

ProPhase Labs  (OTCPK:PRPH) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.

ProPhase Labs Probability of Financial Distress (%) Related Terms

PRPH vs NSTM, IDTA, IVRO: Probability of Financial Distress (%) Comparison

For the Diagnostics & Research subindustry, ProPhase Labs's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProPhase Labs Probability of Financial Distress (%) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Probability of Financial Distress (%) falls into.


ProPhase Labs Probability of Financial Distress (%) Calculation

Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.

The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:

LPFD= -20.12 * NIMTAAVG + 1.60 * TLMTA - 7.88 * EXRETAVG + 1.55 * SIGMA - 0.005 * RSIZE - 2.27 * CASHMTA + 0.070 * MB - 0.09 * PRICE -8.87
=0.20

The Probability of Financial Distress (%) (PFD) was then obtianed by:

PFD=1/(1 + e^(-LPFD))*100%
=54.87%

The eight explanatory variables are:

1. NIMTAAVG = Net Income to Market Total Assets

NIMTAAVG=Net Income / Market Total Assets
=Net Income / (Market Cap + Total Liabilities)

*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.

2. TLMTA = Total liabilities to Market Total Assets

TLMTA=Total Liabilities / Market Total Assets

3. CASHMTA = Cash to Market Total Assets

For non-financial companies, CASHMTA is measured as:

CASHMTA=Cash, Cash Equivalents, Marketable Securities / Market Total Assets

4. EXRETAVG = Excess Return compared to the S&P 500

EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.

5. SIGMA = Standard Deviation of Daily Returns

For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).

6. RSIZE = Relative Size

RSIZE=log (Market Cap / Total Market Cap of S&P 500 companies)

7. MB = Market to Adjusted Book Equity Ratio

MB=Market Cap / Adjusted Book Equity
=Market Cap / (Total Stockholders Equity + 0.1 * ( Market Cap - Total Stockholders Equity))

8. PRICE

PRICE is measured as the log of the stock price, capped at log(15).

What does a Probability of Financial Distress (%) of 54.87% mean?
ProPhase Labs (PRPH) has a Probability of Financial Distress (%) of 54.87% as of Jun. 25, 2026.
Is ProPhase Labs' Probability of Financial Distress (%) too high?
ProPhase Labs' current Probability of Financial Distress (%) is 54.87%.
How does ProPhase Labs' Probability of Financial Distress (%) compare to NSTM and IDTA?
ProPhase Labs' Probability of Financial Distress (%) of 54.87% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Probability of Financial Distress (%) for a Medical Diagnostics & Research company?
A good Probability of Financial Distress (%) depends on the Medical Diagnostics & Research industry context. However, Probability of Financial Distress (%) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Probability of Financial Distress (%) mean?
A high Probability of Financial Distress (%) can signal that a stock is expensive relative to its fundamentals. ProPhase Labs's current Probability of Financial Distress (%) is 54.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.09 — trading 86% below its estimated fair value. The current Probability of Financial Distress (%) is 54.87%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Probability of Financial Distress (%) calculated?
Probability of Financial Distress (%) is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Probability of Financial Distress (%) is 54.87% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProPhase Labs Business Description

Address 626 RXR Plaza, 6th Floor, Uniondale, NY, USA, 11556
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.